GlassScriptPhysician profile
Angela Polk
NPI 1083135271
$4,305.47
in general payments reported to CMS, 2019-2025
38 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $1,357 · 2023: $1,036 · 2024: $1,116 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $710.86 | 2022-2025 | Fasenra, Farxiga, Tezspire |
| Glaxosmithkline, LLC. | $404.59 | 2022-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.90 | 2022-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $370.81 | 2022-2024 | |
| United Therapeutics Corporation | $298.50 | 2021-2024 | Tyvaso |
| Mylan Specialty L.P. | $219.04 | 2022-2024 | Yupelri |
| Insmed, INC. | $217.08 | 2022-2023 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $208.42 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.00 | 2021-2024 | Glassia |
| Merck Sharp & Dohme LLC | $171.11 | 2021-2024 | Zerbaxa, Recarbrio, Dificid |
| Grifols USA, LLC | $107.84 | 2022-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $95.61 | 2022-2024 | Dupixent |
| Amgen INC. | $87.99 | 2021-2024 | Tezspire |
| Pfizer INC. | $72.68 | 2022-2023 | |
| Abbvie INC. | $70.42 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $63.38 | 2025 | V.A.C.Ulta |
| Baxter Healthcare | $55.33 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $54.72 | 2022-2023 | Opsumit |
| Aurinia Pharma U.S., INC. | $42.76 | 2021 | |
| Smith+Nephew, INC. | $41.91 | 2025 | Collagenase Santyl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.90 | 2025 | Caplyta |
| Ani Pharmaceuticals, INC. | $38.83 | 2024 | Purified Cortrophin Gel |
| Lundbeck LLC | $36.71 | 2025 | Rexulti |
| Resmed Corp | $32.26 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $30.07 | 2021 | |
| Janssen Biotech, INC. | $27.81 | 2021 | |
| W. L. Gore & Associates, INC. | $27.43 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Abbott Laboratories | $24.22 | 2025 | Perclose Prostyle |
| Vanda Pharmaceuticals INC. | $20.38 | 2025 | Fanapt |
| Eisai INC. | $18.76 | 2021 | |
| Vifor Pharma, INC. | $16.26 | 2024 | Zemaira |
| Gilead Sciences, INC. | $16.26 | 2021 | |
| Braintree Laboratories, INC. | $15.95 | 2021 | |
| Exact Sciences Corporation | $15.95 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $15.39 | 2021 | |
| Olympus America INC. | $14.21 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.01 | 2021 | |
| Merz North America, INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Polk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.